A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CR / complete hematological remission

[Related PubMed/MEDLINE]
Total Number of Papers: 51
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CR  (>> Co-occurring Abbreviation)
Long Form:   complete hematological remission
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2019 A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy. HD-MTX, MRI, PCNSL, WBRT
2  2019 Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients. FAB, LSCs
3  2019 What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? allo-HCT, AML, GVHD, NRM, RCT
4  2019 [Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome]. ACA, CCyR, CyR, LEN, MDS, OS
5  2018 A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique. DLBCL, HD-MTX, MRI, PCNSL, WBRT
6  2018 Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging. CHT, CI, CMT, HL, HR, PET-CT, PFS, RT
7  2018 How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. CRT, MS, NSCLC, PT-MV
8  2018 Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. allo-HCT, AML, CIR, HR, MRD, NGS, VAF
9  2018 Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. CHC, DAAs, IFN, MC, RBV
10  2018 Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. ALL, MRD
11  2016 Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy. AML, CCR, DFS, NPM1, SWOG
12  2016 Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma. CT, FDG PET-CT, OS, PFS
13  2015 A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases. HAI
14  2015 Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. OS
15  2015 Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. HR
16  2015 Total radiation dose and overall treatment time are predictive for tumor sterilization in cervical carcinoma treated with chemoradiation and pulsed-dose-rate brachytherapy. CTV, HR-CTV, RD
17  2014 Clofarabine/cyclophosphamide for debulking before stem cell transplantation. HSCT, pts
18  2013 Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. AL, BD, MEL, PR, SCT
19  2013 Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. CAPTEM, NETs, PR, SD, TMZ
20  2013 Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy. DCE, DCE-CT, NR, NSCLC, PET, RECIST, RER
21  2013 Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. PR, SLVL/SMZL, SMZL
22  2012 Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. AL, HDM
23  2012 Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization. AFP, HCC, TACE
24  2012 Minimal residual disease in acute myeloid leukemia: coming of age. AML, MRD
25  2012 Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". cTACE
26  2010 Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). SMZL
27  2010 [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis]. CTD, VGPR
28  2009 Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia-Update study. HSCT
29  2007 Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. AML, APL, ATRA, CMR, LSC, RFS
30  2007 Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. HDM/SCT
31  2007 Transurethral Resection of Bladder Tumor (TUR-BT) then Concomitant Radiation and Cisplatin Followed by Adjuvant Gemcitabine and Cisplatin in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder. CCRT, PFS, RC, TCC, TURBT
32  2007 Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. PR, SSCHN
33  2005 Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. CCR, MALT, RD
34  2005 Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. CI, MALT, MALT
35  2005 Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. AML, BR
36  2005 Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. FLC, HDM/SCT, IFE
37  2005 [Acute myeloid leukemia with pulmonary manifestation]. ---
38  2004 A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. GR, MDS, RA
39  2003 Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch. AUC, NRTI, PI, REB, REB
40  2003 Tumor response to induction chemoradiation: influence on survival after esophagectomy. RT
41  2000 Detection of acute promyelocytic leukemia (APL) cells intermediately differentiated by all-trans retinoic acid in the cerebrospinal fluid: central nervous system involvement in APL. APL, ATRA
42  2000 Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction. AML, BMT, FISH, RT-PCR
43  2000 Nodal T cell blast crisis in chronic myeloid leukemia. BC, CML
44  1999 Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. AML
45  1998 Matched unrelated donor marrow transplantation in patients with advanced acute leukemia. AL, ALL, AML, GVHD, HLA, MUD
46  1995 Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia. APL, ATRA, RT-PCR
47  1995 Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia. ALL, BM, CDR3, GMALL, IgH, MRD, PCR, TCR gamma
48  1995 [Rearrangement of the alpha RAR and pml genes in promyelocytic leukemia]. APL
49  1994 Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. EGFR, MR, PCNA, PR
50  1994 Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies. BMT, CT, FISH, metaphase-FISH
51  1992 Shedding of CD9 antigen by bone marrow cells from patients with acute lymphoblastic leukaemia. BM